IRulya Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $211.28M
- P/E (TTM)
- –
- Dividend yield
- –
About IRulya Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Quince Therapeutics, Inc. is a biotechnology company that historically focused on developing therapies for rare diseases by utilizing a patient's own red blood cells for drug delivery. The company's proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform consists of an automated drug and device combination designed to encapsulate drugs into autologous red blood cells to enhance biodistribution, extend half-life, and improve tolerability across small molecules and biologics. Its lead asset was eDSP, which encapsulated dexamethasone sodium phosphate for the treatment of ataxia-telangiectasia. Following disappointing results in its Phase 3 NEAT trial, the company discontinued further clinical development of eDSP and ceased research activities.
The company operates with no other active drug candidates and conducts its principal operations from South San Francisco, California. Having halted pipeline development, it focuses its present activities on cash preservation and the evaluation of potential strategic alternatives.
Summary of the business section of IRulya Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IRulya Therapeutics Inc.
- Founded
- 2012
- Headquarters
- New Haven, CT
- Address
- 101 College Street, Suite 210 06510
- Phone
- (203) 208-8994
- Employees
- 38, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BDO USA, P.C., San Jose, California
Stock & identifiers
- Ticker
- IRLA
- Exchange
- Nasdaq
- IPO date
- May 9, 2019
- Shares outstanding
- 1M, Aug 7, 2026
- Public float
- $64.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Jun 30, 2026; 1-for-10 reverse, May 11, 2026; 1-for-10 reverse, Apr 13, 2026
- SEC CIK
- 1662774
- CUSIP
- 22053A305
- ISIN
- US22053A3059
- EIN
- 90-1024039
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brigette Roberts | Chief Corp. Affairs Officer, Director | – |
| Dirk Thye | CEO and CMO, Director | 994,885 |
| Brendan Hannah | CBO, COO & CCO | 336,547 |
| Charles S. Ryan | President | 130,009 |
| Christopher J. Senner | Director | 0 |
| David Lamond | Director | 6,974,754 |
| Margaret McLoughlin | Director | 8,000 |
| June Bray | Director | – |
| Luca Benatti | Director | 39,179 |
| Una S. Ryan | Director | 2,875 |
| Rajiv Patni | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Thye | $2.41M | $3.94M | $1.17M | $526 | – |
| FY2024 Dirk Thye M.d. | $2.73M | $3.37M | $1.13M | $293 | – |
| FY2024 Dr. Thye | $2.73M | $3.37M | $1.13M | $293 | – |
| FY2023 Casey C.Lynch | $0 | $0 | $1.00M | $165 | – |
| FY2023 Christopher Lowe | $0 | $0 | $1.00M | $165 | – |
| FY2023 Dirk Thye M.d. | $1.33M | $2.49M | $1.00M | $165 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 38 total employees, of which 25 are in research and development and 13 are in general and administrative.”
Corporate history
Events identified from SEC filings